Drug Asset Portfolio
Browse our portfolio of computationally validated drug assets available for licensing or collaboration. Each asset represents deep scientific work ready for experimental validation and partnership.
Teprotumumab Biobetters — Long-Acting Anti-IGF-1R
Keep anti-IGF-1R biology but engineer the Fc (YTE or LS) to extend half-life, enable Q6-8W IV dosing, and support SC formulations. Variant C (T250Q/M428L YTE) is lead with best IGF-1R binding preservation.
Project Epsilon — CNS-Sparing AR Antagonists
Redesign enzalutamide scaffold: thiohydantoin → oxo-hydantoin to increase polarity and reduce BBB penetration. Block N-dealkylation (N-CH₂F, N-CD₃) to harden metabolism and mitigate PXR/CYP induction.
Next-Gen BRAF V600E Inhibitors — Metabolic Soft-Spot Swap
Replace dabrafenib's para-tert-butyl group with rigid, sp³-rich heterobicyclic cages to block soft-spot oxidation, reduce clearance (enable QD), lower LogP, and improve solubility while preserving V600E binding.
CTSB-VEN-001 — Cathepsin B–Activated Venetoclax Prodrug
IV, cathepsin B–cleavable venetoclax prodrug: large, polar, PEGylated construct inert in plasma, cleaved in lysosomes by CTSB to release venetoclax intracellularly. Decouples tumor kill from systemic Cmax for less TLS risk.
TL1A ImmunoPET — Ga-68–NOTA–Fab TL1A Tracer
Same-day immunoPET tracer: human Fab vs TL1A, conjugated with p-SCN-Bn-NOTA and labeled with Ga-68. Fab enables rapid clearance and high contrast within hours for patient selection and target engagement measurement.
Chrono-MUPS — IR NR → ER Metformin for PAD
Chrono-sequenced combo in MUPS: IR nicotinamide riboside pulse to raise NAD⁺ ('redox priming'), then ER metformin to activate AMPK. Exploits NAD⁺–SIRT1–AMPK–PGC-1α coupling to amplify mitochondrial remodeling.
Pyro-PPAR — Lanifibranor + Diroximel Fumarate for MASH
Fixed-dose combo: Lanifibranor (pan-PPAR) for metabolic and direct antifibrotic effects, plus DRF→MMF fumarate to block NLRP3–caspase-1–GSDMD pyroptosis via GSDMD succination. Precision strategy in pyroptosis-high subgroup.
ABX–TEL — Ambroxol + Telmisartan FDC for MSA
Once-daily FDC: Sustained-release ambroxol to chaperone GCase → improved lysosomal function, reduced α-syn. pH-independent IR telmisartan (CNS-penetrant ARB/PPAR-γ agonist) to stabilize BBB and damp neuroinflammation.
Interested in Licensing?
Contact our business development team to discuss licensing opportunities, data packages, and partnership terms for any of our assets.
Contact Licensing Team